𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Enhanced intestinal excretion of hexachlorobenzene in rats by intraluminal injection of hexadecane

✍ Scribed by K. Rozman; T. Rozman; H. Greim


Publisher
John Wiley and Sons
Year
1983
Tongue
English
Weight
325 KB
Volume
3
Category
Article
ISSN
0260-437X

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

The effect of hexadecane on the intestinal excretion of hexachlorobenzene was studied in female Sprague‐Dawley rats dosed twice with ^14^C‐hexachlorobenzene at 50 mg kg^−1^ per os. Injection of 75 mg n‐hexadecane into ligated and unligated segments of the intestine increased concentrations of hexachlorobenzene in intestinal contents by about two‐ or three‐fold in jejunal and ileal segments, and about two‐fold in the cecal—colon segment. The jejunum appeared to be the site of greatest excretion of hexachlorobenzene, followed by the ileum, the cecum and the colon. This order is opposite to our previous data from animals with an undisturbed intestinal passage. The apparently greater excretion of hexachlorobenzene into the small intestine is probably due to its much larger surface area than that of the large intestine. However, the residency time of luminal contents in the large intestine normally exceeds that in the small intestine by about 20–40‐fold, which apparently more than compensates for the difference in relative surface area between small and large intestine. Thus, residency time appears to be a more important factor than surface area in determining the intestinal elimination of hexachlorobenzene. These results with hexachlorobenzene are probably typical of physiological disposition of lipophilic halogenated hydrocarbons generally.


📜 SIMILAR VOLUMES


Enhancement by vaso-active intestinal pe
✍ Hiroyasu Iishi; Masaharu Tatsuta; Miyako Baba; Shigeru Okuda; Haruo Taniguchi 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 French ⚖ 449 KB 👁 1 views

## I The effects of vaso-active intestinal peptide (VIP) on gastric carcinogenesis induced by N-methyl-N'-nitro-N-nitrosoguanidine (MNNG) were investigated in Wistar rats given VIP every other day for 27 weeks after oral administration of MNNG for 25 weeks. In week 52, administration of VIP caused